{"preliminary_commentary":{"by_channel":{"podcast":2,"youtube":1,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"TroFuse-007","nct_id":"NCT06170788","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=trofuse-007-nct06170788. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TroFuse-007","arms":[{"description":"Participants receive sacituzumab tirumotecan via intravenous (IV) infusion on Days 1, 15 and 29 of each 6-week cycle + 400 mg Pembrolizumab every 6 weeks (q6w) via IV infusion on Day 1 of each 6-week cycle for 18 cycles. Additionally, participants receive diphenhydramine (or equivalent), an H2 antagonist of investigator's choice, acetaminophen (or equivalent), and dexamethasone (or equivalent) per each drug's product label prior to the first 4 infusions of sacituzumab tirumotecan. At subsequent infusions, the H2 antagonist and dexamethasone are optional, at the discretion of the investigator.","label":"Pembrolizumab + Sacituzumab tirumotecan","type":"EXPERIMENTAL"},{"description":"Participants receive 400 mg Pembrolizumab via IV infusion q6w on Day 1 of each 6-week cycle for 18 cycles","label":"Pembrolizumab","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-05-27","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer (NSCLC)"],"enrollment":{"count":614,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Sacituzumab tirumotecan","otherNames":["SKB264","MK-2870"],"type":"BIOLOGICAL"},{"name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®","SCH 900475"],"type":"BIOLOGICAL"},{"name":"Supportive care measures","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-15","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-01-25","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 49 months"}],"references":[],"start_date":{"date":"2023-12-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)","url":"https://clinicaltrials.gov/study/NCT06170788"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/trofuse-007-nct06170788"}